For analysis, the bacteria tested were generally placed into genus, species, or other groups with at least 10 isolates. The ranges and the MICs at which 50 and 90% of isolates were inhibited were determined except for organisms with fewer than 10 strains tested, for which only the ranges are reported (Table 8).

OPT-80 had good activity against most anaerobic gram-positive non-spore-forming rods and anaerobic gram-positive cocci. OPT-80 also showed good activity against enterococci and staphylococci.

TABLE 8

In vitro activity of R-Tiacumicin B (>90% Stereomerically Pure) against 453 bacterial isolates

Organism	MIC range	MIC_{50}	MIC_{90}
Bacteroides fragilis group spp. (50)	256->1024	256	>1024
Veillonella spp. (10)	16-128	32	128
Other anaerobic gram-negative rods (51)	0.06-1024	1024	>1024
All anaerobic gram-negative species (111)	0.06->1024	256	>1024
Clostridium bifermentans (9)	0.06	NA	NA
Clostridium bolteae (7)	1-64	NA	NA
Clostridium clostridioforme (4)	4-128	NA	NA
Clostridium difficile (23)	0.06-2	0.12	0.25
Clostridium glycolicum (9)	0.06-1	NA	NA
Clostridium innocuum (9)	32-128	NA	NA
Clostridium paraputrificum (8)	0.06-8	NA	NA
Clostridium perfringens (14)	0.06	0.062	0.062
Clostridium ramosum (10)	256-512	512	512
Clostridium sordellii (5)	0.06	NA	NA
Other clostridial species (9)	0.06->1024	NA	NA
All *Clostridium* species (107)	0.06->1024	0.062	128
Anaerobic non-spore-forming gram-positive rods (63)	0.06->1024	1	32
Anaerobic gram-positive cocci (49)	0.06->1024	0.5	2
All anaerobic gram-positive species (219)	0.06->1024	0.12	64
Streptococcus, formerly *S. milleri* group (14)	16-64	32	32
Other *Streptococcus* species (9)	16-128	NA	NA
Enterococcus species (21)	2.0-16	8	8
Staphylococcus aureus and *Staphylococcus epidermidis* (19)	0.25-2	0.5	2
Total for all strains (453)	0.06->1024	8	1024

Other Embodiments

All references discussed above are herein incorporated by reference in their entirety for all purposes. While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.

What is claimed is:

1. An isolated compound having the formula:



free from other stereoisomers of the compound.

2. A pharmaceutical composition comprising the compound of claim **1** or pharmaceutically acceptable salt thereof.

3. The pharmaceutical composition of claim **2**, further comprising one or more pharmaceutically acceptable carriers.

4. The pharmaceutical composition of claim **3**, wherein the composition is formulated for oral administration.

5. The pharmaceutical composition of claim **4**, wherein the composition is formulated as a tablet.

6. A pharmaceutical composition consisting of the compound of claim **1** or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.

* * * * *